Future of Drug Discovery

• Akan I, Akan S, Akca H, Savas B, Ozben T (2004) N-acetylcysteine enhances multidrug resistance-associated protein mediated doxorubicin resistance. Eur J Clin Invest 34:683–689. doi:10.1111/j.1365-2362.2004.01411.x

  Article  CAS  PubMed  Google Scholar 

• Akan I, Akan S, Akca H, Savas B, Ozben T (2005) Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and buthionine sulfoximine. Cancer Cell Int 5:22. doi:10.1186/1475-2867-5-22

  Article  PubMed  PubMed Central  CAS  Google Scholar 

• Altman MD, Ali A, Reddy GS, Nalam MN, Anjum SG, Cao H, Chellappan S, Kairys V, Fernandes MX, Gilson MK, Schiffer CA, Rana TM, Tidor B (2008) HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc 130:6099–6113. doi:10.1021/ja076558p

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Amrane S, Kerkour A, Bedrat A, Vialet B, Andreola ML, Mergny JL (2014) Topology of a DNA G-quadruplex structure formed in the HIV-1 promoter: a potential target for anti-HIV drug development. J Am Chem Soc 136:5249–5252. doi:10.1021/ja501500c

  Article  CAS  PubMed  Google Scholar 

• Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y (2007) Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72:29–39. doi:10.1124/mol.106.033167

  Article  CAS  PubMed  Google Scholar 

• Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, Bost F (2010) Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70:2465–2475. doi:10.1158/0008-5472.CAN-09-2782

  Article  CAS  PubMed  Google Scholar 

• Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108:2332–2338. doi:10.1182/blood-2006-02-004580

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Brown D (2015) Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat Rev Drug Discov 14:821–832. doi:10.1038/nrd4675

  Article  CAS  PubMed  Google Scholar 

• Burdock GA, Carabin IG, Griffiths JC (2006) The importance of GRAS to the functional food and nutraceutical industries. Toxicology 221:17–27. doi:10.1016/j.tox.2006.01.012

  Article  CAS  PubMed  Google Scholar 

• Byler S, Sarkar S (2014) Do epigenetic drug treatments hold the key to killing cancer progenitor cells? Epigenomics 6:161–165. doi:10.2217/epi.14.4

  Article  CAS  PubMed  Google Scholar 

• Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S (2014) Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 34:1071–1077

  CAS  PubMed  Google Scholar 

• Cao L, Song W, De Clercq E, Zhan P, Liu X (2014) Recent progress in the research of small molecule HIV-1 RNase H inhibitors. Curr Med Chem 21:1956–1967. doi:10.2174/0929867321666140120121158

  Article  CAS  PubMed  Google Scholar 

• Chen CYC (2011) TCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silico. PLoS One 6:e15939. doi:10.1371/journal.pone.0015939

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Cressey D (2011) Traditional drug-discovery model ripe for reform. Nature 471:17–18. doi:10.1038/471017a

  Article  CAS  PubMed  Google Scholar 

• Csermely P, Korcsmáros T, Kiss HJ, London G, Nussinov R (2013) Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther 138:333–408. doi:10.1016/j.pharmthera.2013.01.016

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Dewan V, Liu T, Chen KM, Qian Z, Xiao Y, Kleiman L, Mahasenan KV, Li C, Matsuo H, Pei D, Musier-Forsyth K (2012) Cyclic peptide inhibitors of HIV-1 capsid-human lysyl-tRNA synthetase interaction. ACS Chem Biol 7:761–769. doi:10.1021/cb200450w

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Dihazi GH, Bibi A, Jahn O, Nolte J, Mueller GA, Engel W, Dihazi H (2013) Impact of the antiproliferative agent ciclopirox olamine treatment on stem cells proteome. World J Stem Cells 5:9–25. doi:10.4252/wjsc.v5.i1.9

  Article  PubMed  PubMed Central  Google Scholar 

• Dittmar W, Grau W, Raether W, Schrinner E, Wagner WH (1981) Microbiological laboratory studies with ciclopiroxolamine. Drug Res 31:1317–1322

  CAS  Google Scholar 

• Domadia PN, Bhunia A, Sivaraman J, Swarup S, Dasgupta D (2008) Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry 47:3225–3234. doi:10.1021/bi7018546

  Article  CAS  PubMed  Google Scholar 

• Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BØ (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 104:1777–1782. doi:10.1073/pnas.0610772104

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Ejim L, Farha MA, Falconer SB, Wildenhain J, Coombes BK, Tyers M, Brown ED, Wright GD (2011) Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat Chem Biol 7:348–350. doi:10.1038/nchembio.559

  Article  CAS  PubMed  Google Scholar 

• Ennifar E, Aslam MW, Strasser P, Hoffmann G, Dumas P, van Delft FL (2013) Structure-guided discovery of a novel aminoglycoside conjugate targeting HIV-1 RNA viral genome. ACS Chem Biol 8:2509–2517. doi:10.1021/cb400498n

  Article  CAS  PubMed  Google Scholar 

• Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C (1981) Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66:497–499. doi:10.1093/jnci/66.3.497

  CAS  PubMed  Google Scholar 

• Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438

  CAS  PubMed  Google Scholar 

• Fulda S, Galluzzi L, Kroemer G (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9:447–464. doi:10.1038/nrd3137

  Article  CAS  PubMed  Google Scholar 

• Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A (2014) Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 32:825–837. doi:10.1007/s10637-014-0120-7

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58. doi:10.1038/nrc706

  Article  CAS  PubMed  Google Scholar 

• Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK (2012) Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci USA 109:11178–11183. doi:10.1073/pnas.1204524109

  Article  PubMed  PubMed Central  Google Scholar 

• Herschhorn A, Gu C, Espy N, Richard J, Finzi A, Sodroski JG (2014) A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat Chem Biol 10:845–852. doi:10.1038/nchembio.1623

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233. doi:10.1073/pnas.0400067101

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N (2011) Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem 286:22211–22218. doi:10.1074/jbc.M110.180224

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR (2010) Evidence that opioids may have toll like receptor 4 and MD-2 effects. Brain Behav Immun 24:83–95. doi:10.1016/j.bbi.2009.08.004

  Article  CAS  PubMed  Google Scholar 

• Jacoby E (2011) Computational chemogenomics. Wiley Interdiscip Rev Comput Mol Sci 1:57–67. doi:10.1002/wcms.11

  Article  CAS  Google Scholar 

• Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, Kim WS, Kim JB (2009) Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296:955–964. doi:10.1152/ajpendo.90599.2008

  Article  CAS  Google Scholar 

• Juergens R, Wrangle J, Vendetti F, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, Baylin SB, Brock MV, Rudin CM (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1:598–607. doi:10.1158/2159-8290.CD-11-0214

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Kamal A, Shankaraiah N, Shalini N (2014) Recent horizons in drug discovery and development. Curr Trends Pharm Sci 2:6–11

  Google Scholar 

• Kanadaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT (2005) The antitumor activities of flavonoids. In Vivo 19:895–909

  CAS  PubMed  Google Scholar 

• Kang D, Song Y, Chen W, Zhan P, Liu X (2014) “Old Dogs with New Tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. Mol Biosyst 10:1998–2022. doi:10.1039/c4mb00147h

  Article  CAS  PubMed  Google Scholar 

• Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260–2270. doi:10.1056/NEJMoa1002315

  Article  CAS  PubMed  Google Scholar 

• Kaspar AA, Reichert JM (2013) Future directions for peptide therapeutics development. Drug Discov Today 18:807–817. doi:10.1016/j.drudis.2013.05.011

  Article  CAS  PubMed  Google Scholar 

• Khanna I (2012) Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today 17:1088–1102. doi:10.1016/j.drudis.2012.05.007

  Article  PubMed  Google Scholar 

• Kim SH, Shin DS, Oh MN, Chung SC, Lee JS, Oh KB (2004) Inhibition of the bacterial surface protein anchoring transpeptidase sortase by isoquinoline alkaloids. Biosci Biotechnol Biochem 68:421–424. doi:10.1271/bbb.68.421

  Article  CAS  PubMed  Google Scholar 

• Kim HU, Kim TY, Lee SY (2010) Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE. Mol Biosyst 6:339–348. doi:10.1039/b916446d

  Article  CAS  PubMed  Google Scholar 

• Kitano H (2007) A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6:202–210. doi:10.1038/nrd2195

  Article  CAS  PubMed  Google Scholar 

• Koutsoukas A, Simms B, Kirchmair J, Bond PJ, Whitmore AV, Zimmer S, Young MP, Jenkins JL, Glick M, Glen RC, Bender A (2011) From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics 74:2554–2574. doi:10.1016/j.jprot.2011.05.011

  Article  CAS  PubMed  Google Scholar 

• Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC (1997) Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272:1682–1687. doi:10.1074/jbc.272.3.1682

  Article  CAS  PubMed  Google Scholar 

• Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140:3079–3093. doi:10.1242/dev.091744

  Article  CAS  PubMed  Google Scholar 

• Liscovitch M, Lavie Y (2002) Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5:349–355

  CAS  PubMed  Google Scholar 

• Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC (2000) Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 275:7138–7143. doi:10.1074/jbc.275.10.7138

  Article  CAS  PubMed  Google Scholar 

• Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC (2004) Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J Virol 78:3123–3132. doi:10.1128/JVI.78.6.3123-3132.2004

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Lounkine E, Kutchukian P, Petrone P, Davies JW, Glick M (2012) Chemotography for multi-target SAR analysis in the context of biological pathways. Bioorg Med Chem 20:5416–5427. doi:10.1016/j.bmc.2012.02.034

  Article  CAS  PubMed  Google Scholar 

• Lozano C, Torres JL, Julia L, Jimenez A, Centelles JJ, Cascante M (2005) Effect of new antioxidant cysteinyl-flavanol conjugates on skin cancer cells. FEBS Lett 579:4219–4225. doi:10.1016/j.febslet.2005.06.051

  Article  CAS  PubMed  Google Scholar 

• Lucci A, Giuliano AE, Han TY, Dinur T, Liu YY, Senchenkov A, Cabot MC (1999) Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int J Oncol 15:535–540. doi:10.3892/ijo.15.3.535

  CAS  PubMed  Google Scholar 

• Maga G, Radi M, Gerard MA, Botta M, Ennifar E (2010) HIV-1 RT inhibitors with a novel mechanism of action: NNRTIs that compete with the nucleotide substrate. Viruses 2:880–899. doi:10.3390/v2040880

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Marsden MD, Zack JA (2013) HIV/AIDS eradication. Bioorg Med Chem Lett 23:4003–4010. doi:10.1016/j.bmcl.2013.05.032

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Maxmen A (2011) Translational research: the American way. Nature 478:S16–S18. doi:10.1038/478S16a

  Article  CAS  PubMed  Google Scholar 

• Mbonye U, Karn J (2014) Transcriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cure. Virology 454–455:328–339. doi:10.1016/j.virol.2014.02.008

  Article  PubMed  CAS  Google Scholar 

• Medina-Franco JL, Martínez-Mayorga K, Peppard TL, Del Rio A (2012) Chemoinformatic analysis of GRAS (Generally Recognized as Safe) flavor chemicals and natural products. PLoS One 7:e50798. doi:10.1371/journal.pone.0050798

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K (2014) A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int 2014:186864. doi:10.1155/2014/186864

  PubMed  Google Scholar 

• Mori M, Manetti F, Botta M (2011) Targeting protein-protein and protein-nucleic acid interactions for anti-HIV therapy. Curr Pharm Des 17:3713–3728. doi:10.2174/138161211798220972

  Article  CAS  PubMed  Google Scholar 

• Mullard A (2012) 2011 in reflection. Nat Rev Drug Discov 11:6–8. doi:10.1038/nrd3643

  Article  CAS  PubMed  Google Scholar 

• Mun SH, Joung DK, Kim YS, Kang OH, Kim SB, Seo YS, Kim YC, Lee DS, Shin DW, Kweon KT, Kwon DY (2013) Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine 20:714–718. doi:10.1016/j.phymed.2013.02.006

  Article  CAS  PubMed  Google Scholar 

• Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968. doi:10.1038/nrd2961

  Article  CAS  PubMed  Google Scholar 

• Nalam MN, Schiffer CA (2008) New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr Opin HIV AIDS 3:642–646. doi:10.1097/COH.0b013e3283136cee

  Article  PubMed  PubMed Central  Google Scholar 

• Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M (2011) The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirology 8:101. doi:10.1186/1742-4690-8-101

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B (2003) Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 47:1805–1817. doi:10.1128/AAC.47.6.1805-1817.2003

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412. doi:10.1016/j.ccr.2009.09.028

• Okarvi SM (2008) Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 34:13–26. doi:10.1016/j.ctrv.2007.07.017

  Article  CAS  PubMed  Google Scholar 

• Park BS, Kim JG, Kim MR, Lee SE, Takeoka GR, Oh KB, Kim JH (2005) Curcuma longa L. constituents inhibit sortase A and Staphylococcus aureus cell adhesion to fibronectin. J Agric Food Chem 53:9005–9009. doi:10.1021/jf051765z

  Article  CAS  PubMed  Google Scholar 

• Prabhudesai PP, Jain S, Keshvani A, Kulkarni KP (2011) The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults. J Indian Med Assoc 109:124–127

  CAS  PubMed  Google Scholar 

• Prabu-Jeyabalan M, King NM, Nalivaika EA, Heilek-Snyder G, Cammack N, Schiffer CA (2006) Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 50:1518–1521. doi:10.1128/AAC.50.4.1518-1521.2006

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ (1999a) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80:1005–1011. doi:10.1038/sj.bjc.6690455

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Raghunand N, Martínez-Zaguilán R, Wright SH, Gillies RJ (1999b) pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 57:1047–1058. doi:10.1016/S0006-2952(99)00021-0

  Article  CAS  PubMed  Google Scholar 

• Reymond JL, van Deursen R, Blum LC, Ruddigkeit L (2010) Chemical space as a source for new drugs. MedChemComm 1:30–38. doi:10.1039/C0MD00020E

  Article  CAS  Google Scholar 

• Rullmann JA, Struemper H, Defranoux NA, Ramanujan S, Meeuwisse CM, van Elsas A (2005) Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. IEEE Proc Syst Biol 152:256–262. doi:10.1049/ip-syb:20050053

  Article  CAS  Google Scholar 

• Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259. doi:10.1056/NEJMoa0912614

  Article  CAS  PubMed  Google Scholar 

• Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S (2013a) Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics 5:87–94. doi:10.2217/epi.12.68

  Article  CAS  PubMed  Google Scholar 

• Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M (2013b) Cancer development, progression and therapy: an epigenetic overview. Int J Mol Sci 14:21087–21113. doi:10.3390/ijms141021087

  Article  PubMed  PubMed Central  CAS  Google Scholar 

• Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J (2011) Cyclin E amplification/ overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci USA 108:3761–3766. doi:10.1073/pnas.1014835108

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Segal NH, Verghis J, Govindan S, Maliakal P, Sharkey RM, Wegener WA, Goldenberg DM, Saltz LB (2013) A phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody–drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC). Cancer Res 73:LB-159. doi:10.1158/1538-7445.AM2013-LB-159

• Senchenkov A, Litvak DA, Cabot MC (2001) Targeting ceramide metabolism–a strategy for overcoming drug resistance. J Natl Cancer Inst 93:347–357. doi:10.1093/jnci/93.5.347

  Article  CAS  PubMed  Google Scholar 

• Senter P, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631–637. doi:10.1038/nbt.2289

  Article  CAS  PubMed  Google Scholar 

• Shen Y, Altman MD, Ali A, Nalam MN, Cao H, Rana TM, Schiffer CA, Tidor B (2013) Testing the substrate-envelope hypothesis with designed pairs of compounds. ACS Chem Biol 8:2433–2441. doi:10.1021/cb400468c

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Sloan RD, Wainberg MA (2013) Harnessing the therapeutic potential of host antiviral restriction factors that target HIV. Expert Rev Anti Infect Ther 11:1–4. doi:10.1586/eri.12.146

  Article  CAS  PubMed  Google Scholar 

• Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J (1999) Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10:719–728. doi:10.1097/00001813-199909000-00005

  Article  CAS  PubMed  Google Scholar 

• Steinmann J, Buer J, Pietschmann T, Steinmann E (2013) Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol 168:1059–1073. doi:10.1111/bph.12009

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507–519. doi:10.1038/nrd3480

  Article  CAS  PubMed  Google Scholar 

• Szarc vel Szic K, Ndlovu MN, Haegeman G, Vanden Berghe W (2010) Nature or nurture: let food be your epigenetic medicine in chronic inflammatory disorders. Biochem Pharmacol 80:1816–1832. doi:10.1016/j.bcp.2010.07.029

• Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F (2013) Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 57:3990–3993. doi:10.1128/AAC.00179-13

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Thayer AM (2011) Shifting generics to the super side. Chem Eng News 22–26

  Google Scholar 

• Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR, Fry DW (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 48:2388–2406. doi:10.1021/jm049354h

  Article  CAS  PubMed  Google Scholar 

• Tuske S, Sarafianos SG, Clark AD Jr, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, Wang G, Gaffney BL, Jones RA, Jerina DM, Hughes SH, Arnold E (2004) Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol 11:469–474. doi:10.1038/nsmb760

  Article  CAS  PubMed  Google Scholar 

• Uwagawa T, Misawa T, Iida T, Sakamoto T, Gocho T, Wakiyama S, Hirohara S, Yanaga K (2010) Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients. J Palliat Med 13:815–818. doi:10.1089/jpm.2009.0404

  Article  PubMed  Google Scholar 

• VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J 3rd, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL (2005) Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J Med Chem 48:2371–2387. doi:10.1021/jm049355+

  Article  CAS  PubMed  Google Scholar 

• Vercruysse T, Basta B, Dehaen W, Humbert N, Balzarini J, Debaene F, Sanglier-Cianferani S, Pannecouque C, Mely Y, Daelemans D (2012) A phenyl-thiadiazolylidene-amine derivative ejects zinc from retroviral nucleocapsid zinc fingers and inactivates HIV virions. Retrovirology 9:95. doi:10.1186/1742-4690-9-95

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791. doi:10.1056/NEJMoa1209124

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Vogt A, Lazo JS (2005) Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets. Pharmacol Ther 107:212–221. doi:10.1016/j.pharmthera.2005.03.002

  Article  CAS  PubMed  Google Scholar 

• Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, Lehar J, Wiesmann M, Wartmann M, Chen Y, Cao ZA, Pinzon-Ortiz M, Kim S, Schlegel R, Huang A, Engelman JA (2014) CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26:136–149. doi:10.1016/j.ccr.2014.05.020

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, Adamia S, Wu C, Gray N, Griffin JD (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 115:4206–4216. doi:10.1182/blood-2009-11-251751

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Xue W, Ban Y, Liu H, Yao X (2014) Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis. J Chem Inf Model 54:621–633. doi:10.1021/ci400060j

  Article  CAS  PubMed  Google Scholar 

• Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821. doi:10.1056/NEJMoa1002965

  Article  CAS  PubMed  Google Scholar 

• Zentner I, Sierra LJ, Maciunas L, Vinnik A, Fedichev P, Mankowski MK, Ptak RG, Martin-Garcia J, Cocklin S (2013) Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein. Bioorg Med Chem Lett 23:1132–1135. doi:10.1016/j.bmcl.2012.11.041

  Article  CAS  PubMed  Google Scholar 

• Zhan P, Liu X, De Clercq E (2010) Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Curr Med Chem 17:495–503. doi:10.2174/092986710790416335

  Article  CAS  PubMed  Google Scholar 

• Zhang YM, Rock CO (2004) Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthesis. J Biol Chem 279:30994–31001. doi:10.1074/jbc.m403697200

  Article  CAS  PubMed  Google Scholar 

• Zhao WH, Hu ZQ, Hara Y, Shimamura T (2002) Inhibition of penicillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of penicillin against penicillinase-producing Staphylococcus aureus. Antimicrob Agents Chemother 46:2266–2268. doi:10.1128/AAC.46.7.2266-2268.2002

  Article  CAS  PubMed  PubMed Central  Google Scholar 

• Zhou H, Shen T, Shang C, Luo Y, Liu L, Yan J, Li Y, Huang S (2014) Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway. Oncotarget 5:10140–10150. doi:10.18632/oncotarget.2471

• Zimmermann GR, Lehar J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12:34–42. doi:10.1016/j.drudis.2006.11.008

  Article  CAS  PubMed  Google Scholar 

Download references